CD8A and melanoma: Most importantly, therapeutic vaccination targeted to the tumor-draining lymph nodes (tdLNs) of B16F10 melanoma-bearing mice with Dexo released by DCs co-cultured with oxidized necrotic B16F10 cells as source of melanoma antigens and matured with poly(I:C) (Dexo(B16 + pIC)) raised both melanoma-specific effector CD8+ T cells in the tdLNs, spleen and tumor mass and tumor-infiltrating NK and NK-T cells, significantly reducing tumor growth and increasing the survival rate of diseased mice.